Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide
Küçük Resim Yok
Tarih
2022
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Espana
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Purpose: We designed this study to identify the prognostic value of baseline prognostic nutritional index (PNI) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. Methods: One hundred one mCRPC patients were included. PNI was calculated using formula 10 x serum albumin value (g/dl) + .005 x total lymphocyte count (per mm(3)). ROC analysis was used for determining prognostic PNI value. Results: The statistically significant cut-off value for PNI was 46.62. Initial PSA response and PSA kinetics (early PSA response and 30-50%-90% PSA response at any time) were much better in PNI>46.62 group than the PNI <= 46.62 group (P<.01). In multivariate analysis, baseline PNI level >46.62 was an independent predictor of PSA-PFS (HR: .42; P<.01), radiologic PFS (HR: .53; P<.01), and OS (HR: .42; P<.01). In the PNI <= 46.62 group, median OS was 7.4 months (95% CI: 4.1-10.7) for the abiraterone acetate subgroup vs. 17.6 months (95% CI: 10.1-25.1) for enzalutamide subgroups (P<.01). Conclusion: PNI is a useful, independent prognostic marker for mCRPC patients treated with either abiraterone acetate or enzalutamide. Using pre-treatment PNI may help clinicians in the prediction of survival and decision making based on abiraterone acetate or enzalutamide. (C) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
Açıklama
Anahtar Kelimeler
Prognostic Nutritional Index, Abiraterone Acetate, Enzalutamide, Castration-Resistant Prostate Cancer, Plus Prednisone, Double-Blind, System
Kaynak
Actas Urologicas Espanolas
WoS Q Değeri
Q4
Scopus Q Değeri
Cilt
46
Sayı
5
